Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. A recent study reviews recent developments in ...

Researchers have discovered that activating the pentose phosphate pathway makes antitumor CD8+ T cells more likely to stay in an immature, stem-like, “precursor” state. Combining this metabolic ...

Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger patients and those with a history ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. Studies included in the review were mostly ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. Checkpoint ...